Literature DB >> 23750365

Characterization of Mycobacterium orygis.

Jakko van Ingen, Roland Brosch, Dick van Soolingen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23750365      PMCID: PMC3647658          DOI: 10.3201/eid1903.121005

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: We thank Gey van Pittius and colleagues for their addition to the markers that identify Mycobacterium orygis as a distinct subspecies in the M. tuberculosis complex (). Its isolation from a wild buffalo broadens the host range of M. orygis. Gey van Pittius and colleagues raise 3 issues: the utility of the gyrBoryx single-nucleotide polymorphism (SNP) being equally specific as the reported SNP in Rv2042, the presence of genomic regions RD701 and RD702 in M. orygis, and the addition of the sequence type (ST) 701 spoligotype to M. orygis–specific spoligotypes. We agree that use of the gyrBoryx mutation is more practical for routine daily use because this gene helps identify several subspecies of the M. tuberculosis complex. However, use of the partial Rv2042 sequencing is similarly practical because it can be combined with sequencing of the adjacent pncA gene, which enables identification of several M. tuberculosis complex species and some subspecies (i.e., M. orygis, M. bovis, M. canettii) (), to identify the CAS genotype of M. tuberculosis (J. van Ingen, unpub. data) and, to some degree, assess susceptibility to pyrazinamide (). With the added data, we can conclude that M. orygis is an M. tuberculosis complex subspecies defined by the presence of genomic regions RD1, RD2, RD4, RD5a, RD6, RD13–RD16, RD701, and RD702, by the C-to-G SNP in mmpL6551, and by the deletion of regions RD3, RD5b, RD7-RD12, RDoryx_1, RDoryx_4, and RDoryx_wag22. Subspecies-specific SNPs are present in gyrB and Rv2042. Spoligotypes ST587, ST701, and closely related types are characteristic of M. orygis, and this subspecies yields 17–20 copies of insertion sequence 6110 and a distinct 24-locus variable number tandem repeats pattern (,). Given the rapid progress in genome sequencing, additional markers specific for the different subspecies will further enrich this panel of differences.
  5 in total

1.  Novel genetic polymorphisms that further delineate the phylogeny of the Mycobacterium tuberculosis complex.

Authors:  Richard C Huard; Michel Fabre; Petra de Haas; Luiz Claudio Oliveira Lazzarini; Dick van Soolingen; Debby Cousins; John L Ho
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

2.  Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Sami O Simons; Jakko van Ingen; Tridia van der Laan; Arnout Mulder; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

3.  Infection of African buffalo (Syncerus caffer) by oryx bacillus, a rare member of the antelope clade of the Mycobacterium tuberculosis complex.

Authors:  Nicolaas C Gey van Pittius; Keith D Perrett; Anita L Michel; Dewald F Keet; Tiny Hlokwe; Elizabeth M Streicher; Robin M Warren; Paul D van Helden
Journal:  J Wildl Dis       Date:  2012-10       Impact factor: 1.535

4.  Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies.

Authors:  Jakko van Ingen; Zeaur Rahim; Arnout Mulder; Martin J Boeree; Roxane Simeone; Roland Brosch; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

5.  Characterization of Mycobacterium orygis.

Authors:  Nicolaas C Gey van Pittius; Paul D van Helden; Robin M Warren
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

  5 in total
  1 in total

Review 1.  Microbiological features and clinical relevance of new species of the genus Mycobacterium.

Authors:  Enrico Tortoli
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.